Generic placeholder image

Current Drug Therapy

Author(s): Aashima Barak, Anjali Sharma*, Deepshi Arora, Vishnu Mittal, Akash Gupta and Rohit Grover

DOI: 10.2174/0115748855279099240119110656

DownloadDownload PDF Flyer Cite As
From Pathophysiology to Personalized Treatment Strategies for Psoriasis

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Psoriasis is a chronic inflammatory and proliferative skin disorder characterized by redness and elevated patches covered in scaly, silvery-white skin. The National Psoriasis Foundation categorizes psoriasis into mild, moderate, and severe, impacting 2% to 5% of the global population. This article explores the types, development, and severity categories of psoriasis, delving into its pathophysiology. It also reviews both conventional and herbal topical therapies and their marketed formulations.

Aim: The study aimed to contribute to the development of personalized treatment approaches for individuals with psoriasis. Objectives: This article explores the types, development, and severity categories of psoriasis, delving into its pathophysiology. It also reviews both conventional and herbal topical therapies and their marketed formulations.

Methods: The article relies on a comprehensive review of existing literature and research studies on psoriasis. Information on types, severity categories, pathophysiology, and available treatments, both conventional and herbal, is gathered and analyzed.

Results: The results highlight the potential advantages of incorporating herbal therapies into treatment plans for individuals with psoriasis, especially for those with severe cases.

Conclusion: In conclusion, the article emphasizes the importance of individualized treatment plans for managing psoriasis. Both conventional and herbal topical formulations can be viable options, particularly for severe cases. By considering the safety profiles, side effects, and biological activities associated with these treatments, healthcare experts can collaborate with patients to create personalized and effective strategies for addressing the complexities of psoriasis management.

[1]
Elman SA, Weinblatt ME, Merola JF. Targeted therapies for psoriatic arthritis: An update for the dermatologist. Semin Cutan Med Surg 2018; 37(3): 173-81.
[http://dx.doi.org/10.12788/j.sder.2018.045] [PMID: 30215635]
[2]
Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32(1): 227-55.
[http://dx.doi.org/10.1146/annurev-immunol-032713-120225] [PMID: 24655295]
[3]
Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol 2013; 168(6): 1303-10.
[http://dx.doi.org/10.1111/bjd.12230] [PMID: 23374051]
[4]
Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49(2): 44-50.
[http://dx.doi.org/10.1016/S0190-9622(03)01134-4] [PMID: 12894125]
[5]
Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9(6): 461-7.
[http://dx.doi.org/10.1007/s11926-007-0075-1] [PMID: 18177599]
[6]
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017; 140(3): 645-53.
[http://dx.doi.org/10.1016/j.jaci.2017.07.004] [PMID: 28887948]
[7]
Yiu ZZN, Warren RB. Ustekinumab for the treatment of psoriasis. Semin Cutan Med Surg 2018; 37(3): 143-7.
[http://dx.doi.org/10.12788/j.sder.2018.040] [PMID: 30215630]
[8]
Yang E, Beck K, Sanchez I, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl) 2018; 8: 41-7.
[http://dx.doi.org/10.2147/PTT.S169389] [PMID: 30214891]
[9]
Eberle FC, Brück J, Holstein J, Hirahara K, Ghoreschi K. Recent advances in understanding psoriasis. F1000 Res 2016; 5: 770.
[http://dx.doi.org/10.12688/f1000research.7927.1] [PMID: 27158469]
[10]
Pradhan M, Singh D, Singh MR. Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders. Artif Cells Nanomed Biotechnol 2016; 44(1): 392-400.
[http://dx.doi.org/10.3109/21691401.2014.955105] [PMID: 25229831]
[11]
Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: Prevalence, treatment, and factors associated with biologic use. J Invest Dermatol 2015; 135(12): 2955-63.
[http://dx.doi.org/10.1038/jid.2015.296] [PMID: 26214380]
[12]
Gupta R, Debbaneh MG, Liao W. Genetic epidemiology of psoriasis. Curr Dermatol Rep 2014; 3(1): 61-78.
[http://dx.doi.org/10.1007/s13671-013-0066-6] [PMID: 25580373]
[13]
Gudjonsson JE, Elder JT. Psoriasis: Epidemiology. Clin Dermatol 2007; 25(6): 535-46.
[http://dx.doi.org/10.1016/j.clindermatol.2007.08.007] [PMID: 18021890]
[14]
Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Psoriasis-associated cutaneous pain: Etiology, assessment, impact, and management. J Dermatolog Treat 2018; 19: 1-6.
[PMID: 30256690]
[15]
Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386(9997): 983-94.
[http://dx.doi.org/10.1016/S0140-6736(14)61909-7] [PMID: 26025581]
[16]
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases. J Am Acad Dermatol 2017; 76(3): 377-90.
[http://dx.doi.org/10.1016/j.jaad.2016.07.064] [PMID: 28212759]
[17]
Ortonne JP, Chimenti S, Luger T, Puig L, Reid F, Trüeb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol 2009; 23(12): 1435-44.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03372.x] [PMID: 19614856]
[18]
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361(5): 496-509.
[http://dx.doi.org/10.1056/NEJMra0804595] [PMID: 19641206]
[19]
Ko HC, Jwa SW, Song M, Kim MB, Kwon KS. Clinical course of guttate psoriasis: Long‐term follow‐up study. J Dermatol 2010; 37(10): 894-9.
[http://dx.doi.org/10.1111/j.1346-8138.2010.00871.x] [PMID: 20860740]
[20]
Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol 1996; 132(6): 717-8.
[http://dx.doi.org/10.1001/archderm.1996.03890300147032] [PMID: 8651734]
[21]
Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol 2017; 31(11): 1792-9.
[http://dx.doi.org/10.1111/jdv.14386] [PMID: 28585342]
[22]
Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: Review and treatment of psoriasis. Dis Mon 2019; 65(3): 51-90.
[http://dx.doi.org/10.1016/j.disamonth.2018.06.001] [PMID: 30037762]
[23]
Tagami H. Triggering factors. Clin Dermatol 1997; 15(5): 677-85.
[http://dx.doi.org/10.1016/S0738-081X(97)00024-2] [PMID: 9313966]
[24]
Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984; 110(5): 555-64.
[http://dx.doi.org/10.1111/j.1365-2133.1984.tb04678.x] [PMID: 6232938]
[25]
Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55(1): 62-3.
[http://dx.doi.org/10.1016/j.jdermsci.2009.02.009] [PMID: 19395243]
[26]
Kumar S, Han J, Li T, Qureshi AA, Choi HK, Qureshi AA. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2013; 27(10): 1293-8.
[http://dx.doi.org/10.1111/jdv.12001] [PMID: 23057623]
[27]
Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15(5): 1007-22.
[http://dx.doi.org/10.1016/S0190-9622(86)70265-X] [PMID: 2878015]
[28]
Sondergaard J, Wadskov S, Jensen HA, Mikkelsen HI. Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin). Acta Derm Venereol 1976; 56(3): 239-43.
[http://dx.doi.org/10.2340/0001555556239243] [PMID: 59510]
[29]
Seville RH. Psoriasis and stress. Br J Dermatol 1977; 97(3): 297-302.
[http://dx.doi.org/10.1111/j.1365-2133.1977.tb15186.x] [PMID: 921900]
[30]
Zhou C, Yu X, Cai D, Liu C, Li C. Role of corticotropin-releasing hormone and receptor in the pathogenesis of psoriasis. Med Hypotheses 2009; 73(4): 513-5.
[http://dx.doi.org/10.1016/j.mehy.2009.02.051] [PMID: 19560286]
[31]
Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999; 135(12): 1479-84.
[http://dx.doi.org/10.1001/archderm.135.12.1479] [PMID: 10606053]
[32]
Mills CM, Srivastava ED, Harvey IM, et al. Smoking habits in psoriasis: A case control study. Br J Dermatol 1992; 127(1): 18-21.
[http://dx.doi.org/10.1111/j.1365-2133.1992.tb14818.x] [PMID: 1637689]
[33]
Cuesta-Montero L, Belinchón I. [Connective tissue diseases and psoriasis]. Actas Dermo-Sifiliográficas (English Edition) 2011; 102(7): 487-97.
[http://dx.doi.org/10.1016/j.adengl.2011.03.003] [PMID: 21536244]
[34]
Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin 2015; 33(1): 13-23.
[http://dx.doi.org/10.1016/j.det.2014.09.002] [PMID: 25412780]
[35]
Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007; 33(1-2): 45-56.
[http://dx.doi.org/10.1007/s12016-007-0039-2] [PMID: 18094946]
[36]
Pradhan M, Singh D, Singh MR. Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches. J Control Release 2013; 170(3): 380-95.
[http://dx.doi.org/10.1016/j.jconrel.2013.05.020] [PMID: 23770117]
[37]
Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 2005; 64(2): 30-6.
[http://dx.doi.org/10.1136/ard.2004.031120]
[38]
Sala M, Elaissari A, Fessi H. Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Control Release 2016; 239: 182-202.
[http://dx.doi.org/10.1016/j.jconrel.2016.07.003] [PMID: 27381248]
[39]
Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013; 34(4): 174-81.
[http://dx.doi.org/10.1016/j.it.2012.11.005] [PMID: 23291100]
[40]
Viac J, Palacio S, Schmitt D, Claudy A. Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes. Arch Dermatol Res 1997; 289(3): 158-63.
[http://dx.doi.org/10.1007/s004030050172] [PMID: 9128764]
[41]
Ansel JC, Tiesman JP, Olerud JE, et al. Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J Clin Invest 1993; 92(2): 671-8.
[http://dx.doi.org/10.1172/JCI116636] [PMID: 8349805]
[42]
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445(7130): 866-73.
[http://dx.doi.org/10.1038/nature05663] [PMID: 17314973]
[43]
Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5(9): 699-711.
[http://dx.doi.org/10.1038/nri1689] [PMID: 16138103]
[44]
Chiricozzi A, Pitocco R, Saraceno R, Nistico SP, Giunta A, Chimenti S. New topical treatments for psoriasis. Expert Opin Pharmacother 2014; 15(4): 461-70.
[http://dx.doi.org/10.1517/14656566.2014.875159] [PMID: 24392930]
[45]
Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol 2013; 168(5): 954-67.
[http://dx.doi.org/10.1111/bjd.12276] [PMID: 23413913]
[46]
van de Kerkhof PCM. An update on topical therapies for mild-moderate psoriasis. Dermatol Clin 2015; 33(1): 73-7.
[http://dx.doi.org/10.1016/j.det.2014.09.006] [PMID: 25412784]
[47]
Jacobi A, Mayer A, Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: A systematic review. Dermatol Ther 2015; 5(1): 1-18.
[http://dx.doi.org/10.1007/s13555-015-0068-3] [PMID: 25604924]
[48]
Singh TP, Schön MP, Wallbrecht K, et al. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010; 184(12): 7257-67.
[http://dx.doi.org/10.4049/jimmunol.0903719] [PMID: 20488788]
[49]
Dubertret L. Retinoids, methotrexate and cyclosporine. Curr Probl Dermatol 2009; 38: 79-94.
[http://dx.doi.org/10.1159/000232305] [PMID: 19710551]
[50]
Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg 2004; 8(5): 310-20.
[http://dx.doi.org/10.1177/120347540400800502] [PMID: 15868312]
[51]
Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: Results from a European survey. J Eur Acad Dermatol Venereol 2005; 19(s3) (Suppl. 3): 2-6.
[http://dx.doi.org/10.1111/j.1468-3083.2005.01329.x] [PMID: 16274404]
[52]
Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother 2010; 11(12): 1999-2009.
[http://dx.doi.org/10.1517/14656566.2010.492778] [PMID: 20569091]
[53]
Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001; 23(9): 1339-54.
[http://dx.doi.org/10.1016/S0149-2918(01)80113-2] [PMID: 11589253]
[54]
Pauporte M, Maibach H, Lowe N, et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat 2004; 15(6): 360-4.
[http://dx.doi.org/10.1080/09546630410023566] [PMID: 15764047]
[55]
Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol 1992; 27(6): 1001-8.
[http://dx.doi.org/10.1016/0190-9622(92)70302-V] [PMID: 1479078]
[56]
Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol 2008; 26(4): 380-6.
[http://dx.doi.org/10.1016/j.clindermatol.2008.01.015] [PMID: 18691519]
[57]
Muller KH, Pflugshaupt C. Urea in dermatology I. Hautarzt 1989; 40: 14-8.
[58]
Federman DG, Froelich CW, Kirsner RS. Topical psoriasis therapy. Am Fam Physician 1999; 59(4): 957-962, 964.
[PMID: 10068717]
[59]
Huber C, Christophers E. ’Keratolytic’ effect of salicylic acid. Arch Dermatol Res 1977; 257(3): 293-7.
[http://dx.doi.org/10.1007/BF00741846]
[60]
Clay Cather J, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001; 19(1): 119-137, ix.
[http://dx.doi.org/10.1016/S0733-8635(05)70234-5] [PMID: 11155577]
[61]
Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007; 64(6): 750-7.
[http://dx.doi.org/10.1111/j.1365-2125.2007.02888.x] [PMID: 17425625]
[62]
Mendonça CO, Burden AD. Current concepts in psoriasis and its treatment. Pharmacol Ther 2003; 99(2): 133-47.
[http://dx.doi.org/10.1016/S0163-7258(03)00041-X] [PMID: 12888109]
[63]
Pradhan M, Singh D, Murthy SN, Singh MR. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids 2015; 101: 56-63.
[http://dx.doi.org/10.1016/j.steroids.2015.05.012] [PMID: 26049018]
[64]
OncoSec. What is combination therapy? Available from: https://oncosec.com/2013/09/what-is-combination-therapy/
[65]
Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004; 50(3): 416-30.
[http://dx.doi.org/10.1016/j.jaad.2002.12.002] [PMID: 14988684]
[66]
Facts and statistics about psoriasis Available from: https://www.healthline.com/health/psoriasis/facts-statistics-infographic
[67]
Van De Kerkhof PCM. Therapeutic strategies: Rotational therapy and combinations. Clin Exp Dermatol 2001; 26(4): 356-61.
[http://dx.doi.org/10.1046/j.1365-2230.2001.00829.x] [PMID: 11422189]
[68]
Menter MA, See JA, Amend WJC, et al. Deer Valley, Utah, 7-9 October 1994. Proceedings of the psoriasis combination and rotation therapy conference. J Am Acad Dermatol 1996; 34(2): 315-21.
[http://dx.doi.org/10.1016/S0190-9622(96)80148-4] [PMID: 8642106]
[69]
Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28(3): 454-9.
[http://dx.doi.org/10.1016/0190-9622(93)70067-4] [PMID: 8445062]
[70]
Cambazard , Hutchinson , Haneke , et al. The effect of addition of calcipotriol ointment (50 mug/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138(1): 84-9.
[http://dx.doi.org/10.1046/j.1365-2133.1998.02030.x] [PMID: 9536227]
[71]
Rim JH, Park JY, Choe YB, Youn JI. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: Comparison with acitretin monotherapy. Am J Clin Dermatol 2003; 4(7): 507-10.
[http://dx.doi.org/10.2165/00128071-200304070-00006] [PMID: 12814339]
[72]
De Jong EMGJ, Mørk NJ, Seijger MMB, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: Results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003; 148(2): 318-25.
[http://dx.doi.org/10.1046/j.1365-2133.2003.05173.x] [PMID: 12588386]
[73]
Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002; 6(2): 95-102.
[http://dx.doi.org/10.1177/120347540200600201] [PMID: 11992180]
[74]
Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000; 22(10): 1225-38.
[http://dx.doi.org/10.1016/S0149-2918(00)83065-9] [PMID: 11110233]
[75]
Katoh N, Kishimoto S. Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis. Eur J Dermatol 2003; 13(4): 382-4.
[PMID: 12948920]
[76]
Salmhofer W, Maier H, Soyer HP, Hönigsmann H, Hödl S. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Derm Venereol Suppl 2000; 80(211): 5-8.
[http://dx.doi.org/10.1080/00015550050500022] [PMID: 11234559]
[77]
Austad J, Bjerke JR, Gjertsen BT, et al. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol 1998; 11(1): 19-24.
[http://dx.doi.org/10.1111/j.1468-3083.1998.tb00948.x] [PMID: 9731961]
[78]
Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: A randomised, double-blind trial. Dermatology 2004; 209(4): 308-13.
[http://dx.doi.org/10.1159/000080854] [PMID: 15539894]
[79]
Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48(1): 48-54.
[http://dx.doi.org/10.1067/mjd.2003.130] [PMID: 12522370]
[80]
Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: Results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31(1): 68-74.
[http://dx.doi.org/10.1016/S0190-9622(94)70138-5] [PMID: 8021375]
[81]
Thaçi D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163(2): 402-11.
[http://dx.doi.org/10.1111/j.1365-2133.2010.09791.x] [PMID: 20377585]
[82]
Rhee HJ, Tijssen JGP, Herrmann WA, Waterman AH, Polano MK. Combined treatment of psoriasis with a new aromatic retinoid (Tigason) in low dosage orally and triamcinolone acetonide cream topically: a double-blind trial. Br J Dermatol 1980; 102(2): 203-12.
[http://dx.doi.org/10.1111/j.1365-2133.1980.tb05693.x] [PMID: 6992834]
[83]
Bhuchar S, Katta R, Wolf J. Complementary and alternative medicine in dermatology: An overview of selected modalities for the practicing dermatologist. Am J Clin Dermatol 2012; 13(5): 311-7.
[http://dx.doi.org/10.2165/11597560-000000000-00000] [PMID: 22668453]
[84]
Brown AC, Hairfield M, Richards DG, McMillin DL, Mein EA, Nelson CD. Medical nutrition therapy as a potential complementary treatment for psoriasis--five case reports. Altern Med Rev 2004; 9(3): 297-307.
[PMID: 15387720]
[85]
Brown DJ, Dattner AM. Phytotherapeutic approaches to common dermatologic conditions. Arch Dermatol 1998; 134(11): 1401-4.
[http://dx.doi.org/10.1001/archderm.134.11.1401] [PMID: 9828875]
[86]
Farber EM, Nickoloff BJ, Recht B, Fraki JE. Stress, symmetry, and psoriasis: Possible role of neuropeptides. J Am Acad Dermatol 1986; 14(2): 305-11.
[http://dx.doi.org/10.1016/S0190-9622(86)70034-0] [PMID: 2419375]
[87]
Koo J, Arain S. Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol 1998; 134(11): 1388-93.
[http://dx.doi.org/10.1001/archderm.134.11.1388] [PMID: 9828872]
[88]
Mantle D, Gok MA, Lennard TW. Adverse and beneficial effects of plant extracts on skin and skin disorders. Adverse Drug React Toxicol Rev 2001; 20(2): 89-103.
[PMID: 11482001]
[89]
Deng S, May BH, Zhang AL, Lu C, Xue CCL. Topical herbal medicine combined with pharmacotherapy for psoriasis: A systematic review and meta-analysis. Arch Dermatol Res 2013; 305(3): 179-89.
[http://dx.doi.org/10.1007/s00403-013-1316-y] [PMID: 23354931]
[90]
Joe B, Lokesh BR. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme secretion by rat peritoneal macrophages. Lipids 1997; 32(11): 1173-80.
[http://dx.doi.org/10.1007/s11745-997-0151-8] [PMID: 9397403]
[91]
Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986; 15(3): 504-7.
[http://dx.doi.org/10.1016/S0190-9622(86)70201-6] [PMID: 3760276]
[92]
Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo‐controlled, double‐blind study. Trop Med Int Health 1996; 1(4): 505-9.
[http://dx.doi.org/10.1046/j.1365-3156.1996.d01-91.x] [PMID: 8765459]
[93]
Klein AD, Penneys NS. Aloe vera. J Am Acad Dermatol 1988; 18(4): 714-20.
[http://dx.doi.org/10.1016/S0190-9622(88)70095-X] [PMID: 3286692]
[94]
Robson MC, Heggers JP, Hagstrom WJ Jr. Myth, magic, witchcraft, or fact? Aloe vera revisited. J Burn Care Rehabil 1982; 3(3): 154-63.
[http://dx.doi.org/10.1097/00004630-198205000-00005]
[95]
Choonhakarn C, Busaracome P, Sripanidkulchai B, Sarakarn P. A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol 2010; 24(2): 168-72.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03377.x] [PMID: 19686327]
[96]
Paulsen E, Korsholm L, Brandrup F. A double‐blind, placebo‐controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol 2005; 19(3): 326-31.
[http://dx.doi.org/10.1111/j.1468-3083.2004.01186.x] [PMID: 15857459]
[97]
Dhanabal SP, Priyanka Dwarampudi L, Muruganantham N, Vadivelan R. Evaluation of the antipsoriatic activity of Aloe vera leaf extract using a mouse tail model of psoriasis. Phytother Res 2012; 26(4): 617-9.
[http://dx.doi.org/10.1002/ptr.3589] [PMID: 21915932]
[98]
Reddy S, Aggarwal BB. Curcumin is a non‐competitive and selective inhibitor of phosphorylase kinase. FEBS Lett 1994; 341(1): 19-22.
[http://dx.doi.org/10.1016/0014-5793(94)80232-7] [PMID: 7511111]
[99]
Di Nardo V, Gianfaldoni S, Tchernev G, et al. Use of curcumin in psoriasis. Open Access Maced J Med Sci 2018; 6(1): 218-20.
[http://dx.doi.org/10.3889/oamjms.2018.055] [PMID: 29484027]
[100]
Herrera Acosta E, Alonso Suárez Pérez J, Aguilera Arjona J, Visioli F. An olive polyphenol-based nutraceutical improves cutaneous manifestations of psoriasis in humans. PharmaNutrition 2016; 4(4): 151-3.
[http://dx.doi.org/10.1016/j.phanu.2016.10.002]
[101]
Carson CF, Ashton L, Dry L, Smith DW, Riley TV. Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. J Antimicrob Chemother 2001; 48(3): 450-1.
[http://dx.doi.org/10.1093/jac/48.3.450] [PMID: 11533019]
[102]
Carson CF, Riley TV, Cookson BD. Efficacy and safety of tea tree oil as a topical antimicrobial agent. J Hosp Infect 1998; 40(3): 175-8.
[http://dx.doi.org/10.1016/S0195-6701(98)90135-9] [PMID: 9830588]
[103]
Koh KJ, Pearce AL, Marshman G, Finlay-Jones JJ, Hart PH. Tea tree oil reduces histamine-induced skin inflammation. Br J Dermatol 2002; 147(6): 1212-7.
[http://dx.doi.org/10.1046/j.1365-2133.2002.05034.x] [PMID: 12452873]
[104]
May J, Chan CH, King A, Williams L, French GL. Time-kill studies of tea tree oils on clinical isolates. J Antimicrob Chemother 2000; 45(5): 639-43.
[http://dx.doi.org/10.1093/jac/45.5.639] [PMID: 10797086]
[105]
Zhang J, Li X, Wei J, et al. Gallic acid inhibits the expression of keratin 16 and keratin 17 through Nrf2 in psoriasis-like skin disease. Int Immunopharmacol 2018; 65: 84-95.
[http://dx.doi.org/10.1016/j.intimp.2018.09.048] [PMID: 30293051]
[106]
Stücker M, Memmel U, Hoffmann M, Hartung J, Altmeyer P. Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis. Dermatology 2001; 203(2): 141-7.
[http://dx.doi.org/10.1159/000051729] [PMID: 11586013]
[107]
Ellis CN, Berberian B, Sulica VI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993; 29(3): 438-42.
[http://dx.doi.org/10.1016/0190-9622(93)70208-B] [PMID: 7688774]
[108]
Sarafian G, Afshar M, Mansouri P, Asgarpanah J, Raoufinejad K, Rajabi M. Topical turmeric microemulgel in the management of plaque psoriasis; a clinical evaluation. Iran J Pharm Res 2015; 14(3): 865-76.
[PMID: 26330875]
[109]
Lin YK, Wong WR, Chang YC, et al. The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis. Dermatology 2007; 214(2): 155-61.
[http://dx.doi.org/10.1159/000098576] [PMID: 17341866]
[110]
Lin YK, Chang CJ, Chang YC, Wong WR, Chang SC, Pang JHS. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Arch Dermatol 2008; 144(11): 1457-64.
[http://dx.doi.org/10.1001/archderm.144.11.1457] [PMID: 19015420]
[111]
Gulliver WP, Donsky HJ. A report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experience with Mahonia aquifolium for the treatment of plaque psoriasis. Am J Ther 2005; 12(5): 398-406.
[http://dx.doi.org/10.1097/01.mjt.0000174350.82270.da] [PMID: 16148424]
[112]
DeLong DC, Gerzon K. inventors; Eli Lilly and Co, assignee. Method for treating psoriasis. United States patent US 1976; 3(937): 822.
[113]
Tang J. inventor; HEROSE PHARMA INTERNATIONAL Pte Ltd, assignee. Psoriasis treatment. United States patent application US 2004; 10(268): 650.
[114]
Rosenberg EW, Glenn TM, Skinner RB Jr, Noah PW. inventors; panda pharmaceuticals LLC. Composition and method for treatment of psoriasis. United States patent US 1999; 5(990): 100.
[115]
Di Napoli G. inventor. Substances for use in treating psoriasis. United States patent application US 2005; 10/900: 740.
[116]
Habtemarium S, Stimson WH, Gray AI, Anand CL, Waterman PG. inventors. Use of Calendula glycosides for the treatment of psoriasis. United States patent US 2001; 6(225): 342.
[117]
Sefton J. inventor; Allergan Inc, assignee. Tazarotene and corticosteroid treatment for psoriasis. United States patent US 2011; 8(071): 578.
[118]
Smith SA, Smith LJ. inventors; Smith Steven A, Smith Lorraine J, assignee. Method and composition for treating psoriasis. United States patent US 1992.
[119]
Hunter WL. inventor; Angiotech Pharmaceuticals Inc, assignee. Composition and methods of paclitaxel for treating psoriasis. United States patent US 2003; 6(515): 016.
[120]
Sreedharala VN. inventor; Sarudbhava Formulations Private Ltd, assignee. Apremilast pharmaceutical compositions. United States patent US 2021; 11(110): 077.
[121]
Diamond J. inventor; key pharmaceuticals inc, assignee. systemic treatment of psoriasis using certain salicylates. United States patent US 1984; 4(483): 854.
[122]
Neirinckx R. inventor; Neirinckx Rudi D, assignee. Treatment of psoriasis through down-regulation of the egf-receptor with topically applied egf. United States patent application US 2007; 11/464: 401.
[123]
Hachtel S, Schoenau C, Loehn M, et al. inventors; Sanofi SA, assignee. Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo [3, 4-b] pyridine derivatives as kinase inhibitors. United States patent US 2015; 181
[124]
Platzek J, Niedballa U, Raduechel B, Ebert W, Weinmann HJ, Frenzel T. inventors. 3-, 8-substituted deuteroporphyrin derivatives, pharmaceutical agents that contain the latter, process for their production and their use in photodynamic therapy and MRI diagnosis. Schering AG Assignee. United States patent US 2000; 6(136): 841.
[125]
Friedman M, Licht D, Yacobi A. inventors; Taro Pharmaceutical Industries Ltd, assignee. Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues. United States patent US 2010; 7(678): 366.
[126]
Niedbala RS, Vail EA. inventors; solarcare technologies corp, assignee. compositions and methods for topical treatment of skin lesions. United States patent US 1994; 5(286): 720.
[127]
Zhou JH, Wang Y. Herbal composition and treatment methods. United States patent US 2000; 947
[128]
Smith WJ. inventor. Use of eugenol to treat blisters. United States patent application US 2016; 14/803(004)
[129]
Wulf HC. inventor. Aps Kbus 8 Nr 4788. assignee. Topical treatment of skin disease 2000.
[130]
Sen N. inventors; Cadila Healthcare Ltd, assignee. Topical compositions comprising corticosteroids. United States patent application US 2018; 15/756: 196.
[131]
Goebel AS. inventor; Novaliq GmbH, assignee. Microemulsion pharmaceutical composition comprising a macrolide immunosuppressant drug. United States patent US 2013; 8(574): 562.
[132]
Lipi RE. Inventor; alpes pharmaceuticals ltda, assignee. Topical medicament for the treatment of psoriasis. United States patent application US 2012; 13/503: 641.
[133]
Edinger JW, Hariri RJ, Wang JL, Ye Q, Faleck H. Inventors; Anthrogenesis corp, assignee. treatment of psoriasis using placental stem cells. United States patent US 2014; 8(753): 883.
[134]
Primor N. inventor; SIS Shulov Innovative Science Ltd, assignee. Method for treating disorders of the skin. United States patent US 2015; 397
[135]
Lorca AM. Inventor; psoriasis+ creams swenden ab, assignee. composition for treating psoriasis. United States patent application US 2015; 14/426: 277.
[136]
Hadgraft J. Recent developments in topical and transdermal delivery. Eur J Drug Metab Pharmacokinet 1996; 21(2): 165-73.
[http://dx.doi.org/10.1007/BF03190266] [PMID: 8839691]
[137]
Wertz PW, Madison KC, Downing DT. Covalently bound lipids of human stratum corneum. J Invest Dermatol 1989; 92(1): 109-11.
[http://dx.doi.org/10.1111/1523-1747.ep13071317] [PMID: 2909622]
[138]
De Leeuw J, De Vijlder HC, Bjerring P, Neumann HAM. Liposomes in dermatology today. J Eur Acad Dermatol Venereol 2009; 23(5): 505-16.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03100.x] [PMID: 19175703]
[139]
Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv 2007; 4(4): 297-305.
[http://dx.doi.org/10.2174/156720107782151269] [PMID: 17979650]
[140]
Goyal P, Goyal K, Vijaya Kumar SG, Singh A, Katare OP, Mishra DN. Liposomal drug delivery systems--clinical applications. Acta Pharm 2005; 55(1): 1-25.
[PMID: 15907221]
[141]
Talegaonkar S, Azeem A, Ahmad F, Khar R, Pathan S, Khan Z. Microemulsions: A novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul 2008; 2(3): 238-57.
[http://dx.doi.org/10.2174/187221108786241679] [PMID: 19075911]
[142]
Bali V, Bhavna AM, Ali M, Baboota S, Ali J. Potential of microemulsions in drug delivery and therapeutics: A patent review. Recent Pat Drug Deliv Formul 2008; 2(2): 136-44.
[http://dx.doi.org/10.2174/187221108784534072] [PMID: 19075904]
[143]
Azmin MN, Florence AT, Handjani-Vila RM, Stuart J F B, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 2011; 37(4): 237-42.
[http://dx.doi.org/10.1111/j.2042-7158.1985.tb05051.x] [PMID: 2860220]
[144]
Rogerson A, Cummings J, Willmott N, Florence AT. The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol 2011; 40(5): 337-42.
[http://dx.doi.org/10.1111/j.2042-7158.1988.tb05263.x] [PMID: 2899629]
[145]
Baillie AJ, Coombs GH, Dolan TF, Laurie J. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol 2011; 38(7): 502-5.
[http://dx.doi.org/10.1111/j.2042-7158.1986.tb04623.x] [PMID: 2875149]
[146]
Singh B, Kapil R, Bandopadhyay S, Katare OP. Dendrimers as nanobiopolymers: Drug delivery applications. Pharm Buzz 2009; pp. 34-43.
[147]
Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Temoporfin-loaded invasomes: Development, characterization and in vitro skin penetration studies. J Control Release 2008; 127(1): 59-69.
[http://dx.doi.org/10.1016/j.jconrel.2007.12.013] [PMID: 18281119]
[148]
Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Development of different temoporfin-loaded invasomes—novel nanocarriers of temoporfin: Characterization, stability and in vitro skin penetration studies. Colloids Surf B Biointerfaces 2009; 70(2): 198-206.
[http://dx.doi.org/10.1016/j.colsurfb.2008.12.030] [PMID: 19188048]
[149]
zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism. Eur J Pharm Biopharm 1998; 45(2): 149-55.
[http://dx.doi.org/10.1016/S0939-6411(97)00150-1] [PMID: 9704911]
[150]
Freitas C, Müller RH. Stability determination of solid lipid nanoparticles (SLN TM) in aqueous dispersion after addition of electrolyte. J Microencapsul 1999; 16(1): 59-71.
[http://dx.doi.org/10.1080/026520499289310] [PMID: 9972503]
[151]
Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366(1-2): 170-84.
[http://dx.doi.org/10.1016/j.ijpharm.2008.10.003] [PMID: 18992314]
[152]
Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN ®, NLC ® ). Int J Cosmet Sci 2008; 30(3): 157-65.
[http://dx.doi.org/10.1111/j.1468-2494.2008.00433.x] [PMID: 18452432]
[153]
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50(1): 161-77.
[http://dx.doi.org/10.1016/S0939-6411(00)00087-4] [PMID: 10840199]
[154]
Müller R, Petersen R, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59(6): 522-30.
[http://dx.doi.org/10.1016/j.addr.2007.04.012] [PMID: 17602783]
[155]
Singh B, Bandopadhyay S, Kapil R, Katare OP. Nanostructured lipid carriers as novel drug delivery vehicles. Pharm Buzz 2008; pp. 38-46.